Author:
Kumagai Takashi,Matsuki Eri,Inokuchi Koiti,Ohashi Kazuteru,Shinagawa Atsushi,Takeuchi Jin,Yoshida Chikashi,Okamoto Shinichiro,Wakita Hisashi,Kozai Yasuji,Shirasugi Yukari,Fujisawa Shin,Iwase Osamu,Yano Shingo,Nishiwaki Kaichi,Oba Koji,Sakamoto Junichi,Sakamaki Hisashi
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–82.
3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935–42.
4. Gleevec (imatinib mesylate) tablets: prescribing information, Rev. edn. East Hanover: Novartis Pharmaceuticals, November 2007.
5. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–17.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献